科笛(2487.HK)公布，拟配股2890.4万股新股，占扩大后股本约8.3%；每股配售价8.4港元，较昨日收市价9.55港元折让12.04%；集资2.43亿港元。 公司预计配售所得款项净额约为2.4亿港元，当中，约45%将用于公司在局部脂肪堆积管理、毛发疾病及护理、皮肤疾病及护理以及表皮麻醉管线的临床前研究开发和临床试验，以及用于相应生产设施及设备的布局；约45%将用于CU-40102(外用非那雄胺喷雾剂)及CU-10201(外用4%米诺环素泡沫剂)的市场推广活动、渠道拓展及品牌建设；约10%将用作营运资金及其他一般企业用途。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.